InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
5,702.55
(
-0.19%
)
US TECH 100
19,287.60
(
-0.24%
)
Dow Jones
42,063.36
(
0.09%
)
Brent Oil
74.14
(
0.00%
)
Bitcoin
62,937.37
(
-0.69%
)
Post# of 539
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Keep Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

mlkrborn

Send PM Follow Ignore
Followers 40
Posts 7682
Boards Moderated 1
Alias Born 01/04/2006

mlkrborn

Re: None

Thursday, 05/05/2011 9:29:46 PM

Thursday, May 05, 2011 9:29:46 PM

Post# of 539
ACOR down to $24! 6:11AM Acorda Therapeutics misses by $0.19, misses on revs; maintains AMPYRA rev guidance (ACOR) 27.16 : Reports Q1 (Mar) loss of $0.02 per share, $0.19 worse than the Thomson Reuters consensus of $0.17; revenues rose 246.3% year/year to $61.3 mln vs the $64.2 mln consensus. The co maintains its current year guidance of net revs of $205-$230 mln for AMPYRA. The co reaffirms its full year 2011 R&D expense guidance of $40-45 mln excluding share-based compensation charges.
Public Reply Private Reply New Post
Keep Last Read
Keep Last Read Next 10 Report Keyboard Shortcuts
Next 10 Prev Next
Join InvestorsHub

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up